FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090076603> ?p ?o ?g. }

• W2090076603 endingPage "849" @default.
• W2090076603 startingPage "843" @default.
• W2090076603 abstract "To compare the antileukemic efficacy of idarubicin and mitoxantrone in elderly patients with acute myeloid leukemia (AML) and to evaluate the feasibility of autologous transplantation using PBSC after consolidation in those with a good performance status, 160 patients (median age 69 years), with AML at diagnosis, 118 of them with de novo AML and 42 with AML secondary to myelodysplastic syndrome or toxic exposure (sAML), received induction treatment with idarubicin, 8 mg/m2/day or mitoxantrone, 7 mg/m2/day, on days 1, 3, and 5, both combined with VP-16, 100 mg/m2/day on days 1 to 3 and cytarabine (araC), 100 mg/m2/day, on days 1 to 7. G-CSF, 5 μg/kg/day, was administered after chemotherapy in patients aged more than 70 years. Patients in complete remission (CR) received one course of consolidation using the same schedule as for induction except the araC administration was shortened to 5 days. Some patients younger than 70 years were then scheduled for autologous stem cell harvest on days 5 to 7 of G-CSF, 5 μg/kg/day, initiated after hematopoietic recovery from consolidation. Autologous transplantation was performed following an additional chemotherapy conditioning. Ninety-five patients (59%) achieved CR, without significant difference between the idarubicin (56% CR) and mitoxantrone (63% CR) group. There was also no significant difference in CR rate between de novo AML (63%) and secondary AML (55%) (P = 0.12). Patients aged < 70 years had 67% cr, while patients aged ≥ 70 years had 49% (P = 0.02). There was no significant difference in the duration of aplasia between the two arms. Median time to neutrophil recovery was 22 days in patients who received G-CSF following induction and 27 days in patients who did not (P = 0.006). Severe extra-hematologic toxicities of induction did not differ between the two arms and included sepsis (39%), diarrhea (13%), hyperbilirubinemia (8%), hemorrhage (6%) and vomiting (6%). Overall, 14 patients (9%), died from toxicity of induction. First consolidation was administered in 74 patients of whom seven (9%) died from toxicity. Nineteen patients have received transplantation. Median time to recovery of neutrophils >0.5 × 109/1 was 13 days and of platelets >50 × 109/l 43 days following consolidation. There were two toxic deaths. Median disease-free survival and survival from time of achieving CR of non transplanted patients are 6 and 7 months respectively without difference between the two arms. Fourteen transplanted patients relapsed at a median of 5 months post-transplant. We conclude that this regimen is well tolerated and has a good efficacy to induce CR, without a significant difference in efficacy and toxicity between idarubicin and mitoxantrone. Intensive postinduction, including transplantation, is feasible; however, this procedure did not seem to prevent early relapse in the majority of patients. Neither the high rate of CR nor consolidation nor transplant procedure in a selected group of patients did translate into improved DFS and/or survival." @default.
• W2090076603 created "2016-06-24" @default.
• W2090076603 creator A5011385404 @default.
• W2090076603 creator A5055745584 @default.
• W2090076603 creator A5072721892 @default.
• W2090076603 creator A5074408303 @default.
• W2090076603 creator A5075669839 @default.
• W2090076603 creator A5080855457 @default.
• W2090076603 creator A5085447660 @default.
• W2090076603 creator A5085568292 @default.
• W2090076603 creator A5089177012 @default.
• W2090076603 creator A5091090005 @default.
• W2090076603 date "1999-06-01" @default.
• W2090076603 modified "2023-10-16" @default.
• W2090076603 title "Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia" @default.
• W2090076603 cites W107098111 @default.
• W2090076603 cites W1143126211 @default.
• W2090076603 cites W118967028 @default.
• W2090076603 cites W139860964 @default.
• W2090076603 cites W1492445977 @default.
• W2090076603 cites W1586763410 @default.
• W2090076603 cites W1740151497 @default.
• W2090076603 cites W1861929829 @default.
• W2090076603 cites W1909698311 @default.
• W2090076603 cites W1979300931 @default.
• W2090076603 cites W1990189905 @default.
• W2090076603 cites W1991058838 @default.
• W2090076603 cites W2011564019 @default.
• W2090076603 cites W2013051826 @default.
• W2090076603 cites W2013084492 @default.
• W2090076603 cites W2020851999 @default.
• W2090076603 cites W2079031490 @default.
• W2090076603 cites W2083600033 @default.
• W2090076603 cites W2105643967 @default.
• W2090076603 cites W2112799888 @default.
• W2090076603 cites W2146032483 @default.
• W2090076603 cites W2149998583 @default.
• W2090076603 cites W2150113701 @default.
• W2090076603 cites W2191003384 @default.
• W2090076603 cites W2201158929 @default.
• W2090076603 cites W2211072972 @default.
• W2090076603 cites W2292158797 @default.
• W2090076603 cites W2410089930 @default.
• W2090076603 cites W91972951 @default.
• W2090076603 doi "https://doi.org/10.1038/sj.leu.2401445" @default.
• W2090076603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10360370" @default.
• W2090076603 hasPublicationYear "1999" @default.
• W2090076603 type Work @default.
• W2090076603 sameAs 2090076603 @default.
• W2090076603 citedByCount "62" @default.
• W2090076603 countsByYear W20900766032012 @default.
• W2090076603 countsByYear W20900766032013 @default.
• W2090076603 countsByYear W20900766032015 @default.
• W2090076603 countsByYear W20900766032016 @default.
• W2090076603 countsByYear W20900766032019 @default.
• W2090076603 countsByYear W20900766032020 @default.
• W2090076603 countsByYear W20900766032022 @default.
• W2090076603 crossrefType "journal-article" @default.
• W2090076603 hasAuthorship W2090076603A5011385404 @default.
• W2090076603 hasAuthorship W2090076603A5055745584 @default.
• W2090076603 hasAuthorship W2090076603A5072721892 @default.
• W2090076603 hasAuthorship W2090076603A5074408303 @default.
• W2090076603 hasAuthorship W2090076603A5075669839 @default.
• W2090076603 hasAuthorship W2090076603A5080855457 @default.
• W2090076603 hasAuthorship W2090076603A5085447660 @default.
• W2090076603 hasAuthorship W2090076603A5085568292 @default.
• W2090076603 hasAuthorship W2090076603A5089177012 @default.
• W2090076603 hasAuthorship W2090076603A5091090005 @default.
• W2090076603 hasBestOaLocation W20900766031 @default.
• W2090076603 hasConcept C126322002 @default.
• W2090076603 hasConcept C141071460 @default.
• W2090076603 hasConcept C2776611710 @default.
• W2090076603 hasConcept C2776694085 @default.
• W2090076603 hasConcept C2778041864 @default.
• W2090076603 hasConcept C2778397455 @default.
• W2090076603 hasConcept C2779050716 @default.
• W2090076603 hasConcept C2779117419 @default.
• W2090076603 hasConcept C2780923524 @default.
• W2090076603 hasConcept C2911091166 @default.
• W2090076603 hasConcept C71924100 @default.
• W2090076603 hasConcept C90924648 @default.
• W2090076603 hasConceptScore W2090076603C126322002 @default.
• W2090076603 hasConceptScore W2090076603C141071460 @default.
• W2090076603 hasConceptScore W2090076603C2776611710 @default.
• W2090076603 hasConceptScore W2090076603C2776694085 @default.
• W2090076603 hasConceptScore W2090076603C2778041864 @default.
• W2090076603 hasConceptScore W2090076603C2778397455 @default.
• W2090076603 hasConceptScore W2090076603C2779050716 @default.
• W2090076603 hasConceptScore W2090076603C2779117419 @default.
• W2090076603 hasConceptScore W2090076603C2780923524 @default.
• W2090076603 hasConceptScore W2090076603C2911091166 @default.
• W2090076603 hasConceptScore W2090076603C71924100 @default.
• W2090076603 hasConceptScore W2090076603C90924648 @default.
• W2090076603 hasIssue "6" @default.
• W2090076603 hasLocation W20900766031 @default.
• W2090076603 hasLocation W20900766032 @default.
• W2090076603 hasLocation W20900766033 @default.
• W2090076603 hasOpenAccess W2090076603 @default.

• next